LENSAR (LNSR) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PolyPid (PYPD) has outperformed LENSAR (LNSR) over the past year, gaining 52.5% versus a loss of 46.9%. Over five years, LNSR leads with a -15.3% price change compared with -97.7% for PYPD. PolyPid is the larger company by market cap ($103.0 million vs $78.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNSR | PYPD |
|---|---|---|
| Share price | $6.37 | $5.07 |
| Market cap | $78.26M | $102.98M |
| 1-day change | -1.24% | +3.47% |
| YTD return | -45.23% | +16.82% |
| 1-year return | -46.87% | +52.48% |
| 5-year return | -15.29% | -97.75% |
| P/E ratio (TTM) | 35.39 | — |
| EPS (TTM) | $0.18 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.94 | $5.73 |
| 52-week low | $4.95 | $3.10 |
| Distance from 52-week high | -50.77% | -11.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.86% | +131.76% |
| Average volume | 103.43K | 175.46K |
| Shares outstanding | 12.29M | 20.31M |
| Employees | 150 | 69 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed LNSR by 99.4 percentage points over the past year.
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
LNSR vs PYPD FAQ
Which is bigger, LENSAR or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $102.98M compared with $78.26M for LENSAR (LNSR).
Which stock has performed better over the past year, LNSR or PYPD?
PYPD returned +52.48% over the past 12 months, compared with -46.87% for LNSR (price return, excluding dividends). Past performance does not predict future results.
Are LENSAR and PolyPid in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.